Search research articles
Contact Us
Filters
Showing results (1-10 of 125) with videos related to
Page
of 13
Sort By:
Progress in Clinical and Biological Research
|
January 1, 1987
Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors
E A Grimm
Biochimica Et Biophysica Acta
|
December 17, 1986
Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality
E A Grimm
Cancer Immunology, Immunotherapy : CII
|
January 1, 1986
Inhibition of in vitro LAK generation by OK-432
M Yagita, E A Grimm
Journal of Immunology (Baltimore, Md. : 1950)
|
September 1, 1977
Studies of the induction and expression of T cell mediated immunity. VI. Heterogeneity of lytic efficiency exhibited by isolated cytotoxic T lymphocytes prepared from highly enriched populations of effector-target conjugates
E A Grimm, B Bonavida
Journal of Immunology (Baltimore, Md. : 1950)
|
May 1, 1992
Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction
T Fujiwara, E A Grimm
Cancer Research
|
September 15, 1992
Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells
T Fujiwara, E A Grimm
Journal of Immunology (Baltimore, Md. : 1950)
|
November 1, 1979
Studies on the induction and expression of T cell-mediated immunity. IX. Activation of alloimmune memory lymphocytes into specific secondary CTL by syngeneic NAGO-oxidized stimulator cells
E A Grimm, B Bonavida
Progress in Experimental Tumor Research
|
January 1, 1988
Current understanding of the lymphokine-activated killer cell phenomenon
M Yagita, E A Grimm
Human Immunology
|
March 1, 1995
Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2
K M Heaton, E A Grimm
Cellular Immunology
|
September 1, 1985
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes
E A Grimm, D J Wilson
Page
of 13
Search research articles
Search
Showing results (1-10 of 125) with videos related to
Sort By:
Page
of 13
Progress in Clinical and Biological Research
|
January 1, 1987
Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors
E A Grimm
Biochimica Et Biophysica Acta
|
December 17, 1986
Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality
E A Grimm
Cancer Immunology, Immunotherapy : CII
|
January 1, 1986
Inhibition of in vitro LAK generation by OK-432
M Yagita, E A Grimm
Journal of Immunology (Baltimore, Md. : 1950)
|
September 1, 1977
Studies of the induction and expression of T cell mediated immunity. VI. Heterogeneity of lytic efficiency exhibited by isolated cytotoxic T lymphocytes prepared from highly enriched populations of effector-target conjugates
E A Grimm, B Bonavida
Journal of Immunology (Baltimore, Md. : 1950)
|
May 1, 1992
Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction
T Fujiwara, E A Grimm
Cancer Research
|
September 15, 1992
Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells
T Fujiwara, E A Grimm
Journal of Immunology (Baltimore, Md. : 1950)
|
November 1, 1979
Studies on the induction and expression of T cell-mediated immunity. IX. Activation of alloimmune memory lymphocytes into specific secondary CTL by syngeneic NAGO-oxidized stimulator cells
E A Grimm, B Bonavida
Progress in Experimental Tumor Research
|
January 1, 1988
Current understanding of the lymphokine-activated killer cell phenomenon
M Yagita, E A Grimm
Human Immunology
|
March 1, 1995
Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2
K M Heaton, E A Grimm
Cellular Immunology
|
September 1, 1985
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes
E A Grimm, D J Wilson
Page
of 13